OBJECTIVES: This study aimed to analyse and validate the prognostic impact and effect of the initial recurrence site of lymphovascular and visceral pleural invasion (VPI) on survival outcomes for Stage I non-small-cell lung carcinoma (NSCLC).
INTRODUCTION
Lung cancer is now a major cause of death in developed countries [1] . Despite several improvements in treatment, the all-stage 5-year survival rate of lung cancer is only 15% [1, 2] . Tumour, nodes, metastasis (TNM) stage is the most important factor for predicting the prognosis in lung cancer. The 5-year overall survival (OS) for Stage I patients is 67%. However, even with complete resection by means of lymph node dissection, 30-40% of Stage I patients eventually die of recurrent disease [2, 3] . Therefore, it is important and necessary to identify early-stage patients with a high risk of recurrence, and this identification will be useful to determine the course of action; either by a more careful follow-up and/or additional therapy beyond the standard TNM staging system. Histopathological examination is the most inexpensive method to investigate tumour behaviour, particularly in comparison with molecular methods. Several studies have reported that histopathological factors such as lymphovascular invasion (LVI), visceral pleural invasion (VPI), histopathological grade, lymphocytic tumour infiltration, perineural invasion, mitotic index and nuclear atypia are correlated with prognosis [4] [5] [6] [7] [8] [9] [10] [11] . LVI and VPI are well-examined, and the presence of LVI and/or VPI is associated with worse outcomes in patients with early-stage non-small-cell lung carcinoma (NSCLC) [4, 5] , and most of these patients die because of cancer recurrence. However, till date, the relationship between tumour recurrence site and LVI and/or VPI has not been thoroughly evaluated. Thus, in the present study, we examined the relationship between clinicopathological background, including the outcome of examined patients and tumour recurrence sites, and LVI and VPI.
cancer resection from 1995 to 2010. The pathological stage of each patient was re-evaluated according to the seventh edition of the TNM Classification of the Union for International Cancer Control (UICC) [12] . Patients who underwent neoadjuvant or adjuvant chemotherapy or radiation and those with incomplete resection were excluded. In total, 433 patients with Stage I NSCLC were examined. The study design was approved by the institutional ethics review board. The postoperative follow-up was performed by thoracic surgeons every 3-4 months for 5 years. The evaluations included physical examinations, chest X-rays and chest computed tomography (CT) scanning. Tumour marker examinations, abdominal and brain CTs, and bone scintigraphy were performed annually. Patients were followed up for 5 years, and the surviving patients were regularly followed up with chest, abdominal and brain CTs and bone scintigraphy every year. If patients complained of clinical symptoms, imaging was immediately performed. Patients with cancer recurrence were separated into two groups as determined by the site of initial recurrence into local or distant. Local recurrence was defined as any recurrence site within diseased hemithorax, mediastinum and pleuritis carcinomatosa. All other sites of recurrence were considered as distant metastases. In addition, to compare the survival rate, we reviewed 122 patients with surgically resected pathological stage IIA NSCLC (T1aN1M0, 8 patients; T1bN1M0, 17 patients; T2aN1M0, 67 patients; T2bN0M0, 30 patients) and 51 patients with surgically resected pathological stage IIB NSCLC (T2bN1M0, 10 patients; T3N0M0, 41 patients).
Histopathological evaluation
All specimens were formalin-fixed and stained with haematoxylin and eosin (H&E) and Elastica-Masson (EM) staining. All slides were evaluated by three pathologists (Naoki Yanagawa, Shin-ya Ogata and Gen Tamura) using a multiheaded microscope according to the 2004 WHO classification and the seventh edition of the TNM Classification of UICC, and evaluations were discussed until a consensus was reached [12, 13] . LVI was determined by tumour cells that were identifiable in the lymphatic or blood vessel lumen [14] . Blood vessels were identified by the presence of erythrocytes in the lumen, and/or an endothelial cell lining and/or the presence of elastic tissue around larger vessels. Lymphatic vessels were identified by exclusion. Further, an endothelial-lined channel was considered as a lymphatic vessel if it was devoid of erythrocytes in the lumen and contained few lymphocytes. VPI was determined by the presence of penetration of the thick outer elastic lamina by a tumour during elastic tissue staining according to the guidelines of the seventh edition of the TNM classification for lung cancer [12] .
Statistical analysis
Statistical comparisons were performed using either the χ 2 test or Fisher's exact test or Student-t test, as appropriate. Relapse-free survival (RFS) and OS were analysed using the Kaplan-Meier method, and differences in variables were calculated by the log-rank test. RFS was defined as the time from surgery to recurrence or death or last follow-up. OS was defined as the time from surgery to death or last follow-up. The last follow-up observation was censored if the patient was alive or lost to the follow-up. Multivariate survival analysis was performed using the Cox proportional hazards model. All statistical analyses were performed using Statistical Analysis System version 9.1 (SAS Institute, Inc., Cary, NC, USA). The value of P < 0.05 was considered to be statistically significant.
RESULTS

Patient characteristics
Patient characteristics are given in Table 1 . Of all the patients included, (female, 191 and male, 242; mean age, 67.4; range, 30-88) 196 had no history of smoking, while 237 were either currently smoking or had a smoking history. Adenocarcinoma (ADC) constituted the most common pathological subtype of NSCLC (n = 310) followed by squamous cell carcinoma (n = 99). There were 316 patients in Stage IA and 117 patients in Stage IB. The average tumour size was 2.3 cm (range, 0.5-5 cm). LVI was observed in 41 patients (9.5%), and VPI was observed in 45 (10.4%). Recurrence was observed in 68 patients (15.7%). Regarding initial recurrence sites, distant recurrence was observed in 32 patients (7.4%), and local recurrence was observed in 36 (8.3%).
Lymphovascular invasion
The relationships between LVI and clinicopahological characteristics are given in Table 2 . LVI was strongly correlated with stage (P < 0.001), tumour size (P = 0.004) and recurrence (P < 0.001). Regarding recurrence, there was no difference in the proportion of initial recurrence sites between LVI and No-LVI (distant vs local, 
Visceral pleural invasion
The relationship between VPI and clinicopathological characteristics is given in Table 3 . VPI was strongly correlated with stage (P < 0.001), tumour size (P < 0.001), and recurrence (P < 0.001).
Regarding recurrence, the proportion of local recurrence was higher in the VPI group than that in the No-VPI group (local vs distant, P = 0.014; local vs no recurrence, P < 0.001). For details of the initial recurrence site between the VPI group and the No-VPI group, refer to Supplementary Table SB.
Univariate survival analysis of patient characteristics
Forty-four patients died as a result of their lung carcinoma and another 48 died of other causes during the follow-up period of the study. The mean clinical follow-up period was 67.5 months (range, 0.5-214.9 months). Of the 341 patients alive at the time of analysis, 24 experienced recurrent disease and 317 had no evidence of disease. Therefore, a total of 116 were included in the RFS analysis. Table 4 lists univariate RFS and OS analyses according to clinicopathological backgrounds. Univariate analysis identified the following clinicopathological backgrounds as being significantly associated with worse RFS: male (P = 0.015), age>67 (P < 0.001), smoking (P = 0.011), non-ADC (P < 0.001), both mediastinal and hilar lymph node dissection (P = 0.01), Stage IB (P < 0.001), tumour size >3 cm (P < 0.001), LVI (P < 0.001) and VPI (P < 0.001). The following clinicopathological backgrounds were identified as being significantly associated with worse OS: male (P < 0.01), age > 67 (P < 0.001), smoking (P = 0.002), non-ADC (P < 0.001), both mediastinal and hilar lymph node dissection (P < 0.001), Stage IB (P < 0.001), tumour size >3 cm (P < 0.001), LVI (P < 0.001) and VPI (P = 0.01). The RFS of a combination LVI with various stages are shown in 
Multivariate analysis
On multivariate analysis of RFS, age (P < 0.001, hazards ratio (HR):1.05, 95% confidence interval (CI):1.03-1.08), histology (P = 0.007, HR: 1.90, 95% CI: 1.19-3.03), tumour size (P = 0.037, HR: 1.38, 95% CI: 1.02-1.87), and LVI (P < 0.001, HR: 3.37, 95% CI: 2.07-5.49) were identified as independent predictors of recurrence (Table 5) . Furthermore, on multivariate analysis of OS, age (P < 0.001, HR: 1.07, 95% CI: 1.04-1.10) and LVI (P < 0.001, HR: 2.73, 95% CI: 1.59-4.65) were found to be independent predictors of decreased survival for resected patients with Stage I NSCLC (Table 6 ). VPI was not found to be a significant independent predictor of both RFS and OS in the present study. 
DISCUSSION
The TNM classification staging system provides extensive information for the prognoses of patients and/or therapeutic decisionmaking in NSCLC. However, even with complete resection by means of lymph node dissection, 30-40% of Stage I patients eventually die of recurrent disease [2, 3] . Therefore, different criteria to predict tumour characteristics, such as aggressiveness, are necessary beyond the standard TNM staging system. In the present study, LVI was a significantly independent risk factor for the development of recurrent disease and diminished OS. LVI has been recognized as a poor prognostic factor in various tumours including the colon, breast and head and neck cancers [15] [16] [17] . In lung cancer, recent studies have reported that LVI affects the prognosis of patients undergoing resection for early-stage lung cancer [4, 14, 18] . Tsuchiya et al. (T3N0) is uncertain, we speculate as follows: several patients have vessel invasion, and subsequently distant metastasis might occur and/or adjuvant therapy has been given for the patients of Stage IIA/IIB. The present TNM staging system for lung cancer was published in 2009, in which VPI has been considered as a 'T' factor [12] ; however, LVI has not been reflected as a TNM factor for now. The upstaging of the worst prognostic group of Stage IA and IB NSCLC lends support to the notion of establishing a revised and more complete classification system. VPI has been identified as a pathological variable, and as previously described, VPI has been considered as a T factor; if VPI is found in a patient, it is defined as T2a. Shimizu et al. [7] have reported that VPI is a significant poor prognostic factor in NSCLC, regardless of 'N' status. Furthermore, Kudo et al. [8] have reported that the presence of VPI is an independent poor prognostic factor in patients with NSCLC of ≤7 cm. In the present study, VPI was correlated with a worse outcome in RFS and OS in the univariate analysis. However, in the multivariate analysis, VPI was not found to be a significantly independent predictor of RFS (P = 0.11, HR: 1.68, 95% CI: 0.89-3.17) and OS (P = 0.16, HR: 1.65, 95% CI: 0.82-3.31) in comparison with LVI (P < 0.001).
We have examined several factors and found a difference in initial recurrence sites between patients with LVI and those with VPI. Both LVI and VPI correlated significantly with recurrence, but the proportion of local recurrence in patients with VPI than in those without VPI was significantly higher than that in patients with LVI and those without LVI. The reason for the proportion of local recurrence being significantly higher in patients with VPI remains unclear. However, Kudo et al. [8] have suggested that the visceral pleura is very rich in lymphatic vessels with an intercommunicating network arranged over the lung surface that penetrates into the lung parenchyma to join the bronchial lymph vessels with drainage to various hilar lymph nodes. They have also reported that lung cancer in a sub-pleural location invades the pleura and disseminates cancer cells throughout the pleural cavity, and once exfoliated into the pleural cavity, sub-pleural lymphatics connecting with the pleural space may be responsible for the lymphatic and the subsequent systemic dissemination of tumour cells. In the present study, the proportion of peritonitis carcinomatosa was higher in the VPI group than in the No-VPI group. In contrast, LVI, in particular vascular invasion, rapidly enters the blood circulation and results in distant metastasis. However, in this study, we did not separate vascular invasion from lymphatic invasion and further examination will therefore be needed. As to adaptation to adjuvant therapy, regardless of higher rate of local recurrence in the VPI group, we propose that systemic chemotherapy is required because some VPI groups have distant metastasis.
In conclusion, LVI was associated with a significant reduction in RFS and OS in patients with Stage I NSCLC. LVI was an independent predictor of recurrence and death in these patients. VPI was associated with a significant reduction in RFS and OS in patients with Stage I NSCLC in univariate analysis, but was not an independent predictor of recurrence and death in these patients. There was a significant difference between patients with LVI and those with VPI regarding the initial recurrence site. We propose that LVI and/or VPI may be a candidate marker to determine adjuvant therapy or a more careful follow-up for these patients. Further extensive studies are needed to explore the association between these pathological and molecular features.
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